AAM Slams USMCA Over Mexico Biologics Impact
Doubling Data Exclusivity Will Only Harm Patients, Not Boost Industry
Biologic exclusivity provisions in the proposed USMCA US-Mexico-Canada trade agreement will not create a new market for original biologics in Mexico, as firms have been selling them in the country since before 2001, the US Association for Accessible Medicines has argued in response to brand industry claims.
You may also be interested in...
The AAM has welcomed reports that US negotiators for the proposed US-Mexico-Canada trade agreement could be willing to soften demands on intellectual-property protections for pharmaceuticals, including the data exclusivity period for biologics.
More than 100 members of the US Congress have written to US Trade Representative ambassador Robert Lighthizer urging changes to the US-Mexico-Canada Agreement trade deal that is due to replace the previous NAFTA agreement, with biologic competition and access highlighted as key concerns.
Failure to change provisions of the recently agreed US-Mexico- Canada Free Trade Agreement (USMCA) will “exacerbate the lagging biosimilar market in the US”, slow biosimilar and generic development, and create inconsistencies with US law, according to the US Association for Accessible Medicines (AAM).